Exelixis Inc.

Exelixis Inc. is an oncology-focused biopharmaceutical company specializing in the discovery, development, and commercialization of targeted cancer therapies. Based in Alameda, California and founded in 1994, the company operates as a single business segment dedicated to difficult-to-treat cancers. Exelixis’ portfolio centers on cabozantinib, a multikinase inhibitor marketed in different formulations, which serves as its flagship medicine for various solid tumor indications. In addition, the company has brought to market other oncology and cardiovascular products, including COTELLIC and MINNEBRO, through partnerships with larger pharmaceutical firms. Exelixis runs a broad pipeline of small-molecule and biologic candidates, advancing internally discovered assets and externally sourced programs across multiple mechanisms of action. The company commercializes products directly in the United States and relies on strategic alliances to reach international markets, positioning Exelixis as a significant player in the global market for innovative cancer treatments.